Santhera Pharmaceuticals Holding AG (SWX:SANN)

Switzerland flag Switzerland · Delayed Price · Currency is CHF
15.08
-0.24 (-1.57%)
Apr 3, 2025, 9:39 AM CET
54.35%
Market Cap 192.96M
Revenue (ttm) 113.59M
Net Income (ttm) 62.86M
Shares Out 12.60M
EPS (ttm) 5.70
PE Ratio 2.69
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 7,703
Average Volume 46,169
Open 15.04
Previous Close 15.32
Day's Range 14.80 - 15.08
52-Week Range 7.21 - 17.76
Beta -0.02
RSI 51.96
Earnings Date Apr 29, 2025

About SWX:SANN

Santhera Pharmaceuticals Holding AG, a specialty pharmaceutical company, together with its subsidiaries, develops and commercializes medicines for rare neuromuscular and pulmonary diseases with high unmet medical need in the Europe, North America, and Asia. The company’s lead pipeline candidate includes Vamorolone, which is developed for the treatments of Duchenne muscular dystrophy (DMD). Its clinical stage pipeline also comprises Lonodelestat for the treatment of cystic fibrosis and other neutrophilic pulmonary diseases. Santhera Pharmaceutic... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2004
Employees 45
Stock Exchange SIX Swiss Exchange
Ticker Symbol SANN
Full Company Profile

Financial Performance

Financial Statements

News

Santhera Pharmaceuticals Provides Update on Royalty Agreement for AGAMREE® (Vamorolone) and Warrants held by Idorsia

Pratteln, Switzerland, January 16, 2025 – Santhera Pharmaceuticals (SIX: SANN) announces that Idorsia Pharmaceuticals has entered into a royalty monetization agreement with the R-Bridge Healthcare Fun...

2 months ago - GlobeNewsWire

Santhera Enters into Supply and Distribution Agreement for AGAMREE® (Vamorolone) with Clinigen Group

Pratteln, Switzerland, January 6, 2025 – Santhera Pharmaceuticals (SIX: SANN) announces the signing of an exclusive agreement with Clinigen Group to manage the supply and distribution of AGAMREE® (vam...

3 months ago - GlobeNewsWire

Santhera Announces Approval from China's NMPA for AGAMREE® (Vamorolone) as a Treatment for Duchenne Muscular Dystrophy

China's National Medical Products Administration (NMPA) approved AGAMREE® for the treatment of Duchenne muscular dystrophy in patients aged 4 years and older This approval makes AGAMREE the first and ...

4 months ago - Benzinga

Santhera Pharmaceuticals reports 1H results

7 months ago - Seeking Alpha

Santhera Enters into an Exclusive Distribution Agreement with GENESIS Pharma for AGAMREE® (Vamorolone) in Central and Eastern Europe

Pratteln, Switzerland, September 10, 2024 – Santhera Pharmaceuticals (SIX: SANN) announces the signing of an exclusive distribution agreement with GENESIS Pharma for AGAMREE® (vamorolone) for the trea...

7 months ago - GlobeNewsWire